CN112867502A - Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗 - Google Patents

Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗 Download PDF

Info

Publication number
CN112867502A
CN112867502A CN201980066213.5A CN201980066213A CN112867502A CN 112867502 A CN112867502 A CN 112867502A CN 201980066213 A CN201980066213 A CN 201980066213A CN 112867502 A CN112867502 A CN 112867502A
Authority
CN
China
Prior art keywords
seq
peptide
composition
cells
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980066213.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·德皮尔
L·托能
C·考克斯
P·伯纳文图拉
J·瓦拉德乌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Claude Bernardrian First University
Lyon Bellade Center
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Claude Bernardrian First University
Lyon Bellade Center
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claude Bernardrian First University, Lyon Bellade Center, Institut National de la Santé et de la Recherche Médicale filed Critical Claude Bernardrian First University
Publication of CN112867502A publication Critical patent/CN112867502A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980066213.5A 2018-09-06 2019-09-06 Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗 Pending CN112867502A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306173 2018-09-06
EP18306173.8 2018-09-06
PCT/EP2019/073883 WO2020049169A1 (en) 2018-09-06 2019-09-06 Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine

Publications (1)

Publication Number Publication Date
CN112867502A true CN112867502A (zh) 2021-05-28

Family

ID=63683819

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980066213.5A Pending CN112867502A (zh) 2018-09-06 2019-09-06 Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗

Country Status (12)

Country Link
US (1) US20210330774A1 (cg-RX-API-DMAC7.html)
EP (1) EP3846839A1 (cg-RX-API-DMAC7.html)
JP (2) JP7633930B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210055725A (cg-RX-API-DMAC7.html)
CN (1) CN112867502A (cg-RX-API-DMAC7.html)
AU (1) AU2019334676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3111663A1 (cg-RX-API-DMAC7.html)
IL (1) IL281253B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002519A (cg-RX-API-DMAC7.html)
SG (1) SG11202102290RA (cg-RX-API-DMAC7.html)
WO (1) WO2020049169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000006973A1 (it) 2020-04-02 2021-10-02 Istituto Naz Tumori Irccs Fondazione G Pascale Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro
US11791123B2 (en) 2021-04-29 2023-10-17 Electronics And Telecommunications Research Institute X-ray tube
CN119032273A (zh) 2022-01-25 2024-11-26 艾尔维缪恩公司 用于鉴定herv衍生的表位的新方法
WO2023242343A1 (en) 2022-06-15 2023-12-21 Immunoscape Pte. Ltd. Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535308A (ja) * 2002-06-13 2005-11-24 カイロン コーポレイション Hml−2ポリペプチド発現用ベクター
WO2006103562A2 (en) * 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
CN101557823A (zh) * 2006-07-21 2009-10-14 加利福尼亚大学董事会 人内源性逆转录病毒多肽组合物和其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4950645A (en) 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2002046477A2 (en) * 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
WO2003106634A2 (en) * 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535308A (ja) * 2002-06-13 2005-11-24 カイロン コーポレイション Hml−2ポリペプチド発現用ベクター
WO2006103562A2 (en) * 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
CN101557823A (zh) * 2006-07-21 2009-10-14 加利福尼亚大学董事会 人内源性逆转录病毒多肽组合物和其使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARY L. JOHANNING等: "Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype", SCIENTIFIC REPORTS, vol. 7, 6 February 2017 (2017-02-06), pages 41960, XP055940398, DOI: 10.1038/srep41960 *

Also Published As

Publication number Publication date
IL281253B1 (en) 2024-03-01
WO2020049169A1 (en) 2020-03-12
BR112021004244A2 (pt) 2021-05-25
CA3111663A1 (en) 2020-03-12
MX2021002519A (es) 2021-06-18
IL281253A (en) 2021-04-29
AU2019334676A1 (en) 2021-04-01
IL281253B2 (en) 2024-07-01
KR20210055725A (ko) 2021-05-17
EP3846839A1 (en) 2021-07-14
AU2019334676B2 (en) 2025-06-05
JP2021536479A (ja) 2021-12-27
JP2025003964A (ja) 2025-01-14
SG11202102290RA (en) 2021-04-29
JP7633930B2 (ja) 2025-02-20
US20210330774A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP4926714B2 (ja) Bcl−2ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
JP2024045573A (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
US10688165B2 (en) Medicament for use in a method of inducing or extending a cellular cytotoxic immune response
JP2025003964A (ja) 抗癌ワクチンのための共有腫瘍抗原としてのherv-k由来抗原
US20160199469A1 (en) Oncology vaccine
AU2008257791B2 (en) P53 peptide vaccine
US20150250864A1 (en) Anti-cancer vaccines
JP6619788B2 (ja) Hiv用の免疫学的組成物
KR20220143812A (ko) B형 간염 바이러스와 관련된 질병의 치료
JP2011506497A5 (cg-RX-API-DMAC7.html)
WO2013175258A1 (en) Novel melanoma antigen peptide and uses thereof
JP5890769B2 (ja) がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp)
EP2852611B1 (en) Novel melanoma antigen peptide and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination